Who are the key players in North America Nuclear Medicine & Stable Isotopes Market industry?

The top five key players are Cardinal Health, GE Healthcare, Curium, Bracco Imaging, and Nordion (a Sotera Health company). These companies are renowned for their advanced radiopharmaceutical production, wide product portfolios, robust distribution networks, and continuous investment in research and development for diagnostic and therapeutic nuclear medicine solutions.

Which segment accounted for the largest North America Nuclear Medicine & Stable Isotopes Market share?

The diagnostic segment, particularly SPECT (Single Photon Emission Computed Tomography), held the largest share in the North America market. This dominance is attributed to rising prevalence of cancer and cardiovascular diseases, with radiotracers such as Technetium-99m being widely used for effective imaging in clinical diagnostics.

What are the factors driving the North America Nuclear Medicine & Stable Isotopes Market?

Recent drivers include technological advancements, rising prevalence of chronic diseases, and increased adoption of targeted therapies. For instance, Cardinal Health’s expansion of its nuclear pharmacy services, and partnerships with hospitals for improved radiopharmaceutical supply chains, have significantly bolstered market growth in the region.

Which type accounted for the largest North America Nuclear Medicine & Stable Isotopes Market share?

Technetium-99m dominated the stable isotopes market, given its extensive use in diagnostic imaging procedures such as SPECT. Its favorable half-life, cost-effectiveness, and wide application for cardiac, bone, and oncologic imaging have made it the leading type in the North America nuclear medicine market.

Home Healthcare

North America Nuclear Medicine & Stable Isotopes Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

Name: North America Nuclear Medicine & Stable Isotopes Market
Brand: Bussiness Insights

North America Nuclear Medicine & Stable Isotopes Market Market: by Type (Diagnostic, Therapeutic, Research, Industrial, Others), Application (Oncology, Cardiology, Neurology, Thyroid, Orthopedics, Others), Distribution Channels (Direct Tenders, Retail Sales, Online Sales, Distributors, Hospitals & Clinics, Others), Technology (SPECT, PET, Cyclotron, Radiopharmacy, Others), Organization Size (Small, Medium, Large) and By North America Historical & Forecast Period (2020-2035) Comprehensive Study 2025

Last Updated: 31-07-2025 | Format: PDF | Report ID:20454 | Author: Lily

RD TOC Segmentation Research Methodology Request For Free Sample

North America Nuclear Medicine & Stable Isotopes Market Outlook 2025-2035

The North America Nuclear Medicine & Stable Isotopes Market is experiencing significant expansion driven by technological innovations and a rising prevalence of chronic diseases. Nuclear medicine leverages radioactive substances for diagnosis, treatment, and research, with stable isotopes used extensively in various industrial and medical applications. This market encompasses diagnostic techniques like PET and SPECT, therapeutic radioisotopes, and the distribution and use of stable isotopes in both research and industry. Several factors—including increased adoption of advanced imaging, personalized medicine, and new radiopharmaceutical approvals—are fueling market growth, while challenges around supply chains, regulatory compliance, and high initial costs present persistent hurdles. With a robust healthcare infrastructure and substantial investments from leading players, North America is well-positioned to maintain its market dominance through to 2035.

Latest Market Dynamics

Key Drivers

Growing integration of artificial intelligence into nuclear medicine workflows is optimizing image analysis and improving predictive outcomes. GE Healthcare's 2024 release of an AI-powered platform demonstrates accelerating digitalization in the sector.
Rapid expansion of theranostics—combining diagnostics and therapeutics—led by Curium Pharma’s advances in targeted radiotherapies, is contributing to personalized oncology, making treatments more precise and effective.

Increased investment in cyclotron and radiopharmacy infrastructure, as evidenced by Bracco Imaging's 2024 North American expansion, is expected to unlock greater clinical availability and research applications for novel isotopes.
Rising demand for personalized medicine and molecular imaging opens new avenues for biotech collaborations, with Lantheus Holdings partnering with academic centers in 2024 to advance targeted imaging agents.

High cost of cyclotron installation and radiopharmaceutical production remains restrictive for small and medium providers. Nordion’s reporting in 2024 indicated substantial capital barriers for entry and expansion.
Stringent regulatory and radioactive handling requirements demand significant compliance investments; this was highlighted in 2024 by new NRC rules impacting operational flexibility for radiopharmacies.

The North America Nuclear Medicine & Stable Isotopes Market by type is dominated by diagnostic applications, reflecting the broad deployment of imaging agents in clinical practice. This segment commands over half of the total market due to ongoing advances in PET and SPECT technologies and their routine use in oncology and cardiology. Therapeutic uses are also expanding, driven by new approvals in targeted radionuclide therapies. Research and industrial types have a smaller yet significant presence, supporting innovation and non-medical isotope usage. The market breakdown demonstrates a well-established foothold for diagnostics with growth potential in therapy and research sectors.

Oncology continues to be the predominant application of nuclear medicine and stable isotopes in North America, reflecting their essential role in cancer diagnosis and therapy. Cardiology is the second largest segment, supporting the evaluation of myocardial health and perfusion studies. Neurology applications are on the rise as novel tracers for Alzheimer’s and Parkinson’s gain ground. Other areas like thyroid and orthopedics constitute a smaller share but remain important for the diversification of nuclear medicine’s clinical reach.

The revenue trajectory of the North America Nuclear Medicine & Stable Isotopes Market from 2020 to 2035 shows continuous growth as medical and research demands rise. The market is estimated at USD 7,450 Million in 2025 and is projected to surpass USD 15,200 Million by 2035, reflecting a robust CAGR driven by expanding clinical applications, increased access to isotopes, and steady adoption of next-generation technologies. This sustained growth underlines the critical importance of both diagnostic and therapeutic nuclear medicine to modern healthcare.

The YOY growth of the North America Nuclear Medicine & Stable Isotopes Market has been steady, averaging 7.2% between 2020 and 2025, and is expected to trend at approximately 6% through 2035. Peaks are projected in periods of major technological introductions, such as new PET tracers or theranostics. However, the market may experience brief slowdowns due to regulatory changes or supply disruptions, before rebounding with subsequent innovation and commercialization cycles.

Among North American countries, the United States commands the largest share by a wide margin, owing to its advanced healthcare system, abundant nuclear medicine facilities, and presence of major pharmaceutical and biotech companies. Canada occupies the second largest portion, supported by government-funded research and isotope production, while Mexico’s market, though smaller, is witnessing expansion due to increasing healthcare investments.

The market is highly consolidated, with Cardinal Health leading at 19%, followed by Siemens Healthineers and Curium Pharma, holding 15% and 13% respectively. GE Healthcare, Bracco Imaging, and Nordion collectively comprise a significant share, while a competitive fringe of specialized manufacturers and distributors rounds out the market. This landscape highlights the dominance of established multinationals alongside rising regional innovators.

Hospitals & clinics form the primary customer base, responsible for 63% of purchases due to the high utilization of nuclear medicine in clinical diagnostics and treatment. Research institutions and contract research organizations account for 15% as they expand their usage of stable isotopes and imaging agents in R&D activities. Direct tenders and government buyers, including public health initiatives and academic medical centers, make up the remainder, reflecting efforts to broaden access and innovation.

Metrics	Details
Years	2020-2035
Base Year	2025
Market Size	7450
Regions	United States, Canada, Mexico
Segments	Type: Diagnostic, Therapeutic, Research, Industrial, Others; Application: Oncology, Cardiology, Neurology, Thyroid, Orthopedics, Others
Players	Cardinal Health, Siemens Healthineers, Curium Pharma, Nordion, Lantheus Holdings, Bracco Imaging, NTP Radioisotopes, Eckert & Ziegler, GE Healthcare, Jubilant Radiopharma, Pharmalucence, Mallinckrodt, Advanced Accelerator Applications, NorthStar Medical Radioisotopes, IsoTex Diagnostics

June 2024: Siemens Healthineers announces FDA clearance of their next-gen PET/CT system for advanced oncology imaging.
July 2024: NorthStar Medical Radioisotopes reports successful commissioning of U.S.-based Mo-99 radioisotope production facility.
August 2024: GE Healthcare launches an AI-assisted image analysis platform for nuclear medicine, enhancing workflow efficiency.
September 2024: Bracco Imaging expands its radiopharmaceuticals manufacturing capabilities in North America to meet rising demand.
October 2024: Curium Pharma receives approval for novel targeted radiotherapeutic agent for prostate cancer treatment in the United States.

About the Author

Lily

Senior Market Research Analyst

Lily is a Senior Market Research Analyst specializing in market research, industry analysis, and business consulting across Healthcare. Lily brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lily has helped organizations translate data into actionable growth strategies.

HealthcareMarket ResearchIndustry AnalysisStrategic Consulting

Key Questions Answered

»What is the market size and growth rate of the global and regional market by various segments?
»What is the market size and growth rate of the market for selective countries?
»Which region or sub-segment is expected to drive the market in the forecast period?
»What factors are estimated to drive and restrain the market growth?
»What are the key technological and market trends shaping the market?
»What are the key opportunities in the market?
»What are the key companies operating in the market?
»Which company accounted for the highest market share?

Download Sample

Why Choose Bussiness Insights?

»Strong Industry Focus
»Extensive Product Offerings
»Customer Research Services
»Robust Research Methodology
»Comprehensive Reports
»Latest Technological Developments
»Value Chain Analysis
»Potential Market Opportunities
»Growth Dynamics
»Quality Assurance
»Post-sales Support
»Regular Report Updates

Speak to Analyst

North America Nuclear Medicine & Stable Isotopes Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2035)

North America Nuclear Medicine & Stable Isotopes Market Outlook 2025-2035

Latest Market Dynamics

Key Drivers

Key Trends

Key Opportunities

Key Challenges

Key Restraints

Market Share by Type, 2025

Market Share by Applications, 2025

Market Revenue (USD Million), 2020-2035

Year-on-Year Growth (%), 2020-2035

Market Share by Regions, 2025

Market Players Share, 2025

Market Buyers Share, 2025

Study Coverage

Key Recent Developments

Frequently Asked Questions

About the Author

Related Reports